Related Experiment Video
Updated: Nov 19, 2025

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain
Published on: March 8, 2024
Meralgia Paresthetica Successfully Treated with Palmithoylethanolamide
Rocco Salvatore Calabrò1,2,3,4, Carmela Casella1,2,3,4, Alfredo Manuli1,2,3,4
1Drs. Calabrò and Manuli are with IRCCS Centro Neurolesi "Bonino Pulejo" in Messina, Italy.
Palmitoylethanolamide (PEA) effectively treated a patient with meralgia paresthetica (MP), a nerve entrapment condition. This suggests PEA may be a viable non-surgical option for peripheral neuropathies like MP.
Area of Science:
- Neurology
- Pain Management
- Pharmacology
Background:
- Meralgia paresthetica (MP) is an uncommon entrapment mononeuropathy causing thigh numbness and paresthesia.
- Palmitoylethanolamide (PEA) is recognized for its therapeutic effects in chronic pain and neuropathic conditions.
Observation:
- A case study involved a 28-year-old patient experiencing posttraumatic MP for three months.
- The patient was otherwise healthy, indicating MP as the primary condition.
Findings:
- Successful treatment of MP was achieved using Palmitoylethanolamide (PEA) at a dosage of 1200mg/day.
- The patient experienced symptom resolution, indicating PEA's efficacy in managing MP.
Implications:
- PEA demonstrates potential as a therapeutic agent for peripheral neuropathies, including meralgia paresthetica.
- Further research into PEA for neuropathies could lead to non-invasive treatment alternatives, potentially avoiding surgery.
Related Concept Videos
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease IV: Nursing Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

